Avtozma Injection, Solution
Product Images NDC 72606-042

Product Visual Gallery

This gallery contains 42 technical images submitted to the FDA as part of the official labeling for Avtozma (NDC 72606-042). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celltrion Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Avtozma 01)

A line graph showing the percentage of ACR20 responders over time (weeks 2 to 24) for three treatment groups: Placebo + MTX, ACTEMRA 8 mg/kg + MTX, and ACTEMRA 4 mg/kg + MTX. The y-axis represents percentage of responders with error bars indicating standard error, and the x-axis represents weekly visits. ACTEMRA groups show higher response rates than Placebo over the study period.*

FDA Label Image

Figure 2 (Avtozma 02)

A forest plot chart comparing risk differences and 95% confidence intervals for mortality across four studies and an overall analysis. The chart shows the number of deaths and percentages in standard of care versus Actemra plus standard of care groups, illustrating risk difference values with markers on a horizontal axis ranging from -20 to 20.*

FDA Label Image

Figure A (Avtozma 03)

An instructional illustration showing the before and after use states of a prefilled syringe for AVTOZMA (tocilizumab) injection. It labels the syringe components including the orange plunger rod, white finger flange, viewing window, needle guard, needle, medicine inside the syringe before use, and the cap before and after removal.*

FDA Label Image

Figure B (Avtozma 04)

An instructional illustration showing items included for administration of AVTOZMA (tocilizumab) injection: a carton containing a prefilled syringe, a cotton ball or gauze with an alcohol swab, an adhesive bandage, and an FDA-cleared sharps disposal container.*

FDA Label Image

Figure C (Avtozma 05)

An illustration showing a rectangular product box with a focus on the expiration date area, displayed as a placeholder label 'EXP: YYYY/MM.' The image highlights where the expiration date is typically printed on the packaging.*

FDA Label Image

Figure D (Avtozma 06)

An instructional illustration showing the expiration date location on a syringe or injection device for AVTOZMA (tocilizumab) solution for intravenous injection. The image highlights where to find the expiration date printed on the syringe barrel in the format YYYY/MM.*

FDA Label Image

Figure E (Avtozma 07)

An instructional illustration showing a syringe with an orange plunger and a gray body partially filled with solution. Above the syringe is a clock face icon displaying "30 minutes," likely indicating a time-related instruction for use or administration.*

FDA Label Image

Figure F (Avtozma 08)

An instructional illustration showing a syringe with a colored plunger being inserted into a vial or cartridge, with an enlarged circular inset highlighting the needle tip and the connection area inside the vial or cartridge. This diagram likely depicts a step in preparing or administering the injection solution.*

FDA Label Image

Figure G (Avtozma 09)

An instructional illustration depicting hands being washed under a running faucet. Water flows from the tap onto the hands positioned over a basin or sink, demonstrating hand hygiene or cleansing procedure.*

FDA Label Image

Figure H (Avtozma 10)

An anatomical illustration showing recommended injection sites for AVTOZMA. Gray areas (shoulders) are designated for caregiver and healthcare professional use only. White areas (abdomen and thighs) are for self-injection, caregiver, and healthcare professional use.*

FDA Label Image

Figure I (Avtozma 11)

An instructional illustration depicting a hand applying a small adhesive patch to the front of a thigh. The person is seated with legs bent at the knee, and the adhesive patch is placed on the upper thigh area.*

FDA Label Image

Figure J (Avtozma 12)

Illustration showing hands holding and separating parts of a medical device or injection assembly, with bidirectional arrows indicating removal or detachment. An inset circle depicts discarding a small component into a waste container.*

FDA Label Image

Figure K (Avtozma 13)

An instructional illustration showing two methods of inserting a needle into the skin. The upper part depicts holding the needle at a 45-degree angle or perpendicular (90 degrees) as indicated by a diagram with 'OK' marking both angles. The lower part similarly shows an alternative method holding the needle with the same acceptable angles. The image demonstrates proper needle insertion angles for intravenous injection.*

FDA Label Image

Figure L (Avtozma 14)

An instructional illustration showing a hand holding a syringe-like device with an orange component, positioned near a patient's skin for an injection. A close-up view highlights the orange part on the device. The image appears to demonstrate preparation or use of an injection device for administrating medication, consistent with intravenous injection procedures.*

FDA Label Image

Figure M (Avtozma 15)

Illustration showing a hand holding a syringe with an attached device, positioned above a person's arm. A black arrow points upward, indicating the direction of syringe or device movement. This instructional image likely demonstrates part of the administration process for AVTOZMA injection, solution.*

FDA Label Image

Figure N (Avtozma 16)

An instructional illustration showing a hand placing a syringe into a sharps disposal container. The image emphasizes safe syringe disposal technique and proper handling.*

FDA Label Image

Figure A (Avtozma 17)

An instructional diagram showing a prefilled injection pen device before and after use. The before use image labels the body, window area, blue needle cover with needle inside, and the removable orange cap covering the needle. The after use image shows the blue needle cover locked with the needle inside and an orange indicator visible through the window area signaling "injection complete".*

FDA Label Image

Figure B (Avtozma 18)

Illustration showing components included with the AVTOZMA injection package: a carton containing an auto-injector, cotton ball or gauze and an alcohol swab, an adhesive bandage, and an FDA-cleared sharps disposal container.*

FDA Label Image

Figure C (Avtozma 19)

An instructional illustration showing a close-up of a rectangular product carton with an expiration date label marked as 'EXP: YYYY/MM'. The image highlights where to find the expiration date on the packaging, but does not show other product details.*

FDA Label Image

Figure D (Avtozma 20)

Illustration showing an injection pen device with a zoomed-in view highlighting the location of the expiration date format (YYYY/MM) on the device. No specific product branding or dosage strength is shown in the image.*

FDA Label Image

Figure E (Avtozma 21)

An illustration showing a clock face indicating 45 minutes, above a depiction of a cylindrical medical injection device with a capped end. The image may be instructive for timing or administration guidance related to the injection device.*

FDA Label Image

Figure F (Avtozma 22)

Illustration showing a tube-like device with a magnified view of a rectangular internal component. The image likely depicts part of the AVTOZMA intravenous injection solution packaging or administration device without text or labeling details.*

FDA Label Image

Figure G (Avtozma 23)

An instructional illustration showing a pair of hands being washed under running water from a faucet. The image depicts the hand hygiene process, likely demonstrating how to properly clean hands.*

FDA Label Image

Figure H (Avtozma 24)

Illustration showing recommended injection sites for AVTOZMA (tocilizumab) administration. White-shaded areas indicate locations for self-injection or by caregiver and healthcare professional (HCP), including abdomen, front thighs, and arms. Gray-shaded areas indicate injection sites restricted to caregiver and HCP only, shown on the back part of the upper arms.*

FDA Label Image

Figure I (Avtozma 25)

An instructional illustration showing a person applying a patch to the upper thigh area. The image depicts the person's hand placing a small adhesive patch on the skin, suggesting topical or transdermal medication application technique.*

FDA Label Image

Figure J (Avtozma 26)

An instructional illustration showing removal of the needle cover from an injection pen or device. The image includes hands lifting the orange needle cover upward from the device, with a labeled pointer indicating the needle cover. A circular inset shows safe disposal of the needle cover into a sharps container.*

FDA Label Image

Figure K (Avtozma 27)

An instructional illustration showing a hand holding a syringe or injection pen with a zoomed-in view highlighting a detail on the device, positioned near a person's upper arm, indicating the site for an injection.*

FDA Label Image

Figure L (Avtozma 28)

An instructional illustration showing two methods for holding and administering an injection with a syringe at a 90-degree angle to the injection site, either from above or from the side, depicting correct technique for intravenous or subcutaneous injection.*

FDA Label Image

Figure M (Avtozma 29)

An instructional illustration showing how to use a device, with two sequential steps. The first step shows a hand pressing down on the device labeled "1st click," and the second step shows pressing again labeled "2nd click." The final instruction below states to then count slowly to 5.*

FDA Label Image

Figure N (Avtozma 30)

An instructional illustration showing a hand holding an injection pen with a visible dose indicator, positioned above a bent arm. The image highlights the dose window on the injection pen, suggesting an injection process for a drug like AVTOZMA (tocilizumab) injection, solution administered intravenously.*

FDA Label Image

Figure O (Avtozma 31)

An instructional illustration showing a hand holding a pen-like device with a blue tip and a red indicator, positioning it into or above a rectangular receptacle with a recessed slot. The image appears to demonstrate a step in handling or disposing of the device.*

FDA Label Image

Principal Display Panel (80 mg/4 mL Vial Carton)

Packaging label for Avtozma (tocilizumab-anoh) injection, 80 mg/4 mL (20 mg/mL) for intravenous infusion after dilution. The label indicates single-dose vial use, discard unused portion, and contains 4 vials per package. Manufactured and distributed by Celltrion USA, Inc. Storage instructions and ingredients details are included along with a barcode and NDC 72606-042-02.*

FDA Label Image

Principal Display Panel (200 mg/10 mL Vial Carton)

Packaging label for Avtozma (tocilizumab-anoh) Injection 200 mg/10 mL (20 mg/mL) for intravenous infusion after dilution. The label indicates single-dose vials in a pack of four. Manufactured by Celltrion USA, Inc., the label includes storage instructions, ingredients, and a barcode.*

FDA Label Image

Principal Display Panel (400 mg/20 mL Vial Carton)

Carton packaging label for Avtozma 400 mg/20 mL (20 mg/mL) injection solution for intravenous infusion after dilution. The label indicates a single-dose vial, contains 4 vials per carton, and lists Celltrion USA, Inc. as the labeler. The label includes storage instructions and ingredients, with barcode and regulatory information.*

FDA Label Image

Principal Display Panel (162 mg/0.9 mL Prefilled Syringe Carton)

Packaging label for Avtozma (tocilizumab-anoh) Injection, 162 mg/0.9 mL, a single-dose prefilled syringe for subcutaneous use. The label includes usage instructions, a depiction of the syringe with safety guard, and details of the manufacturer and distributor, Celltrion USA, Inc. The label emphasizes dispensing the enclosed Medication Guide to each patient.*

FDA Label Image

Principal Display Panel (162 mg/0.9 mL Prefilled Syringe Carton)

Container label for Avtozma (tocilizumab-anoh) Injection, 162 mg/0.9 mL. The label indicates the product is for subcutaneous use only and contains four single-dose prefilled syringes with safety guard. Manufactured by Celltrion and distributed by Celltrion USA, Inc., it includes usage instructions and listed components. NDC 72606-045-02.*

FDA Label Image

Principal Display Panel (4 Prefilled Syringe Carton)

Box packaging label for Avtozma (tocilizumab-anoh) Injection, 162 mg/0.9 mL. The label indicates it is for subcutaneous use only and contains 4 single-dose prefilled syringes with safety guard. The product is manufactured by Celltrion and distributed by CELLTRION USA, Inc. The label includes product composition, NDC 72606-045-03, and instructions to dispense the medication guide to each patient.*

FDA Label Image

Rincipal Display Panel (12 Prefilled Syringe Carton)

Packaging label for Avtozma (tocilizumab-anoh) Injection, 162 mg/0.9 mL. This multipack contains 12 single-dose prefilled syringes with safety guard for subcutaneous use only. The label includes storage and usage instructions, contents of the multipack, and manufacturer information for Celltrion USA, Inc. The design shows an illustration of a prefilled syringe and states the product is Rx only.*

FDA Label Image

Principal Display Panel (162 mg/0.9 mL Autoinjector Carton)

Packaging label for Avtozma (tocilizumab-anoh) Injection, 162 mg/0.9 mL, for subcutaneous use only. The label displays the product name, strength, dosage form as a single-dose autoinjector, and NDC 72606-045-04. Manufactured by CELLTRION, Inc. and distributed by CELLTRION USA, Inc. The label includes instructions to dispense the enclosed medication guide.*

FDA Label Image

Principal Display Panel (162 mg/0.9 mL Autoinjectors Carton)

Carton label for Avtozma (tocilizumab-anoh) Injection, 162 mg/0.9 mL, a subcutaneous injection. The packaging contains 4 single-dose autoinjectors and includes a medication guide. Manufactured by CELLTRION, Inc. and distributed by CELLTRION USA, Inc. The label includes storage and usage instructions and the NDC 72606-045-05.*

FDA Label Image

Principal Display Panel (4 Autoinjectors Carton)

Avtozma (tocilizumab-anoh) Injection 162 mg/0.9 mL is a subcutaneous use-only injection. The label shows a carton for 4 single-dose autoinjectors. It includes manufacturer Celltrion, Inc. and distributor Celltrion USA, Inc. The carton emphasizes dispensing the enclosed medication guide to patients and displays relevant NDC and usage information.*

FDA Label Image

Principal Display Panel (12 Autoinjectors Carton)

Packaging label for Avtozma (tocilizumab-anoh) Injection 162 mg/0.9 mL for subcutaneous use only. The multipack contains 12 single-dose autoinjectors (three cartons with four autoinjectors each). Labeler is CELLTRION USA, Inc. The label includes dosing information, contents, storage instructions, and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.